article thumbnail

Building Patient Trust: Identifying Patients Eligible for Pneumococcal Vaccination

Drug Topics

Panelists discuss how pharmacists can systematically identify eligible patients through team-based approaches involving technicians and student pharmacists who can query databases by age (50+) and high-risk conditions or medications, while addressing common barriers identified in research including insurance coverage, patient willingness, eligibility (..)

article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Under GDUFA III alone, DPD published 32 GDUFA guidance documents and MAPPs to ensure the successful implementation of GDUFA.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking Pharmacy Value Through Payer Program Engagement

Drug Topics

This tool helps pharmacies do the following: Identify nondispensing revenue opportunities within their current workflow Reduce administrative burdens Enable staff-wide participation in value-based care programs Provide real-time notifications and intervention opportunities Offer benchmarking and performance tracking capabilities Address data and coordination (..)

article thumbnail

Strategies for digital success in hospital pharmacy

Hospital Pharmacy Europe

In response to this, the Leeds Teaching Hospitals NHS Trust (LTHT) pharmacy team has recently launched its ‘Digital Induction’ document. Initial feedback has been overwhelmingly positive, leading to the creation of additional documents tailored for line managers and pharmacy students with specific digital needs.

article thumbnail

Pharmacy Leaders Enhance Culture with Continuous Learning | McKesson ideaShare

Drug Topics

Regular performance reviews, goal-setting, and clear documentation aren't just administrative tasks—they're critical shields against potential workplace conflicts and legal challenges. Equally important is her emphasis on structured human resources practices.

article thumbnail

Reports Document FDA Review Delays: What Drugmakers Should Know Now

The FDA Law Blog

By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process.

article thumbnail

AI Act: data governance and compliance strategy implications in Pharma

European Pharmaceutical Review

Successful collaboration therefore hinges on dynamic, well documented protocols for anonymisation, consent, role allocation, transparency and ongoing compliance, all balanced against the pace of AI driven innovation: Anonymisation versus technical utility: Only data that have been irreversibly anonymised fall outside GDPR scope.